NDA 021514 · Noven Pharms INC
Daytrana
Methylphenidate · Transdermal · Central Nervous System Stimulant
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Apr 6, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
456
101 Phase 3, 37 recruiting
FAERS reports
29,057
11,071 serious, 1,117 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION Methylphenidate Transdermal System has a high potential for abuse and misuse, which can lead to the development of substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Methylphenidate Transdermal System, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing Methylphenidate Transdermal System, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout Methylphenidate Transdermal System treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see...
What it is approved for
From the label in effect Sep 25, 2025.
Methylphenidate Transdermal System (methylphenidate transdermal system) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Limitations of Use The use of Methylphenidate Transdermal System is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.8 ), Use in Specific Populations ( 8.4 )] . Methylphenidate Transdermal System is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. ( 1 ) Limitations of Use The use of Methylphenidate Transdermal System is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.8 , 8.4 ).
Mechanism: Methylphenidate is a CNS stimulant. Its mode of therapeutic action in ADHD is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 29, 2010 Supplement 10 · Efficacy LetterLabel
- Apr 6, 2006 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form Other Important Information from FDAPediatric Medical ReviewPediatric Clinical Pharmacology Review
4 products under this application
- DAYTRANA · METHYLPHENIDATE 20MG/9HR (2.2MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- DAYTRANA · METHYLPHENIDATE 10MG/9HR (1.1MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- DAYTRANA · METHYLPHENIDATE 30MG/9HR (3.3MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
- DAYTRANA · METHYLPHENIDATE 15MG/9HR (1.6MG/HR) · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Methylphenidate" as an intervention, any sponsor and status, largest first.
- International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity DisorderStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00863499 · 1,344 participants (planned) · Start Oct 2009 · Primary completion Dec 2019
Drug: Short Acting Methylphenidate; Long Acting Methylphenidate · For: Attention Deficit/Hyperactivity Disorder
Sites: Colton, California; Tarzana, California; Englewood Cliffs, New Jersey · 7 sites in all
- Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity DisorderPivotal-lookingCompleted
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Industry
NCT00866996 · 1,323 participants
Drug: Methylphenidate extended-release; Atomoxetine · For: Attention Deficit Hyperactivity Disorder
- Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)Pivotal-lookingCompleted
McGill UniversityAcademic, hospital or other
NCT00483106 · 885 participants · Start Nov 1999 · Primary completion Mar 31, 2020
Drug: Ritalin; Placebo · For: Attention Deficit Hyperactivity Disorder
Sites: Montreal, Canada
- Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01074294 · 740 participants · Start Mar 16, 2010 · Primary completion Jun 20, 2011
Drug: OPDC-34712; Placebo and 1 more · For: Attention Deficit Hyperactivity Disorder
Sites: Little Rock, Arkansas; Beverly Hills, California; Irvine, California · 35 sites in all
- Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01259492 · 725 participants · Start Nov 2010 · Primary completion Aug 2012
Drug: Placebo; Ritalin LA 20 mg and 1 more · For: Attention Deficit/Hyperactivity Disorder
Sites: Little Rock, Arkansas; Beverly Hills, California; Spring Valley, California · 68 sites in all
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
NCT02951754 · 600 participants (planned) · Start Feb 2002 · Primary completion Dec 2032
Drug: Immediate-release Methylphenidate · For: Attention Deficit Disorder With Hyperactivity
Sites: Porto Alegre, Brazil
- A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity DisorderPivotal-lookingCompleted
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Industry
NCT00326300 · 560 participants · Start Apr 2006
Drug: methylphenidate hydrochloride extended-release tablets · For: Attention Deficit Hyperactivity Disorder
- Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01552902 · 549 participants · Start Apr 3, 2012 · Primary completion May 22, 2014
Drug: Lisdexamfetamine dimesylate; Methylphenidate Hydrochloride and 1 more · For: Attention-deficit/Hyperactivity Disorder
Sites: Dothan, Alabama; Tucson, Arizona; Little Rock, Arkansas · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event6,896
- off label use5,958
- product quality issue5,247
- drug ineffective2,929
- drug administration error1,901
- wrong technique in drug usage process1,772
- application site erythema1,699
- drug dose omission1,478
- incorrect drug administration duration1,191
- wrong technique in product usage process1,157
- drug prescribing error1,079
- disturbance in attention916
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 26 |
| 2006 | 49 |
| 2007 | 97 |
| 2008 | 54 |
| 2009 | 79 |
| 2010 | 202 |
| 2011 | 1,878 |
| 2012 | 2,128 |
| 2013 | 2,081 |
| 2014 | 1,924 |
| 2015 | 1,950 |
| 2016 | 2,578 |
| 2017 | 3,505 |
| 2018 | 1,650 |
| 2019 | 1,355 |
| 2020 | 1,139 |
| 2021 | 1,236 |
| 2022 | 1,347 |
| 2023 | 1,537 |
| 2024 | 1,483 |
| 2025 | 1,544 |
| 2026 | 1,205 |
Recalls
42 FDA enforcement reports for this application.
Mar 10, 2023 · Class II · Ongoing
Defective Delivery System: Out of specification for shear.
Mar 10, 2023 · Class II · Ongoing
Defective Delivery System: Out of specification for shear.
Mar 10, 2023 · Class II · Ongoing
Defective Delivery System: Out of specification for shear.
Mar 10, 2023 · Class II · Ongoing
Defective Delivery System: Out of specification for shear.
Nov 16, 2022 · Class II · Ongoing
Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive properties of the transdermal patches.
Jun 24, 2022 · Class II · Ongoing
Defective Delivery System: Customer complaints received for ripping patches and tight release/adhesive transfer.
May 6, 2022 · Class II · Ongoing
Defective Delivery System: customer complaints exceeded respective action limits.
May 20, 2021 · Class II · Ongoing
Defective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the action limits.
Shortages
FDA's drug shortage list.
Current · updated Oct 16, 2026
Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65). Distributed by Padagis US LLC
Current · updated Oct 16, 2026
Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65). Distributed by Padagis US LLC
Current · updated Oct 16, 2026
Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65). Distributed by Padagis US LLC
Current · updated Oct 16, 2026
Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65). Distributed by Padagis US LLC
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Daytrana (Methylphenidate)
2024 spending
$144K
Beneficiaries
158
703 claims
Per beneficiary
$911
$6.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $659,391 |
| 2021 | $751,867 |
| 2022 | $708,936 |
| 2023 | $428,541 |
| 2024 | $143,903 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S, Adamo N, Del Giovane C, et al. · Lancet Psychiatry 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Methylphenidate and Atomoxetine in Pregnancy and Possible Adverse Fetal Outcomes: A Systematic Review and Meta-Analysis.
di Giacomo E, Confalonieri V, Tofani F, et al. · JAMA Netw Open 2024 · Systematic Review, Meta-Analysis
- Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Farhat LC, Lannes A, Del Giovane C, et al. · Lancet Psychiatry 2025 · Systematic Review, Comparative Study
- Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis.
Carucci S, Balia C, Gagliano A, et al. · Neurosci Biobehav Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis.
Isfandnia F, El Masri S, Radua J, et al. · Neurosci Biobehav Rev 2024 · Meta-Analysis, Systematic Review
- Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
Farhat LC, Flores JM, Avila-Quintero VJ, et al. · JAMA Psychiatry 2024 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Noven Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.